stoxline Quote Chart Rank Option Currency Glossary
Merus N.V. (MRUS)
56.55  -2.29 (-3.89%)    07-17 16:00
Open: 57.94
High: 59.38
Volume: 973,884
Pre. Close: 58.84
Low: 55.67
Market Cap: 3,746(M)
Technical analysis
2024-07-17 5:28:59 PM
Short term     
Mid term     
Targets 6-month :  71.57 1-year :  83.59
Resists First :  61.27 Second :  71.57
Pivot price 56.26
Supports First :  54.62 Second :  50.5
MAs MA(5) :  57.31 MA(20) :  56.03
MA(100) :  48.88 MA(250) :  35.49
MACD MACD :  1.1 Signal :  1.1
%K %D K(14,3) :  67.9 D(3) :  66.3
RSI RSI(14): 53.8
52-week High :  61.61 Low :  19.8
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ MRUS ] has closed below upper band by 46.7%. Bollinger Bands are 9.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 59.43 - 59.73 59.73 - 59.92
Low: 54.98 - 55.36 55.36 - 55.61
Close: 56 - 56.58 56.58 - 56.95
Company Description

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Headline News

Sun, 14 Jul 2024
Merus (NASDAQ:MRUS) Sees Strong Trading Volume - Defense World

Fri, 12 Jul 2024
Merus (NASDAQ:MRUS) Sees Strong Trading Volume - MarketBeat

Mon, 01 Jul 2024
Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer - StockTitan

Sat, 01 Jun 2024
Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts - Simply Wall St

Tue, 28 May 2024
Merus announces $300M public offering for clinical developments -

Tue, 28 May 2024
Merus N.V. Announces Proposed Public Offering of Common Shares - GlobeNewswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 67 (M)
Shares Float 47 (M)
Held by Insiders 6.5 (%)
Held by Institutions 80 (%)
Shares Short 6,840 (K)
Shares Short P.Month 3,480 (K)
Stock Financials
EPS -2.74
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.94
Profit Margin 0 %
Operating Margin -593.4 %
Return on Assets (ttm) -24.9 %
Return on Equity (ttm) -52.8 %
Qtrly Rev. Growth -41.6 %
Gross Profit (p.s.) 0
Sales Per Share 0.56
EBITDA (p.s.) -2.44
Qtrly Earnings Growth 0 %
Operating Cash Flow -150 (M)
Levered Free Cash Flow -129 (M)
Stock Valuations
PE Ratio -20.72
PEG Ratio 2.2
Price to Book value 9.5
Price to Sales 99.36
Price to Cash Flow -25.43
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android